Device Trial Radar · NCT03632954
Cytal® Wound Matrix and MicroMatrix® Wound Study
Last checked: Nov 20, 2026Latest source record: May 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
37
Actual
Start
Dec 11, 2018
Primary completion
Jan 27, 2020
Study completion Jan 27, 2020
Sponsor
- Lead sponsor
- Integra LifeSciences CorporationPublic (IART)
- Sponsor type
- Industry
- Collaborators
- Winthrop University Hospital
- First posted
- Aug 16, 2018
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an observational study to assess the safety and efficacy of MicroMatrix® alone or in combination with Cytal® Wound Matrix on primary measures of wound healing.
Conditions
- Wounds
Interventions
ACell ArmDevice
Cytal® Wound Matrix and/or MicroMatrix®
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Completely Healed WoundsTime frame: Up to 12 weeks
- Wound Size ChangeTime frame: Up to 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NYU Winthrop Hospital
Long Island City, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.